Pliant Therapeutics Inc
Cerrado
1.17 2.63
Resumen
Variación precio
24h
Mínimo
1.15
Máximo
1.17
Ingresos | -2.3M -22M |
|---|---|
BPA | -0.36 |
Empleados | 49 |
EBITDA | -2.4M -22M |
Próximas Ganancias | 4 nov 2026 |
|---|
Capitalización Mercado | 7.4M 72M |
|---|---|
Apertura anterior | -1.46 |
Cierre anterior | 1.17 |
Pliant Therapeutics Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Pliant Therapeutics Inc previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.